Effects of the SERM Raloxifene on Calcium and Phosphate Metabolism in Healthy Middle-aged Men

Overview

Journal Clin Cases Miner Bone Metab

Date 2012 Mar 31

PMID 22461168

Citations 5

Authors

Brigitte Uebelhart

Francois Herrmann

Rene Rizzoli

Affiliations

Soon will be listed here.

Abstract

Background. Sex hormones are important regulators of calcium and phosphate homeostasis. Estradiol appears to be a major determinant of bone health in the male gender. However, physiological effects of estrogens on calcium and phosphate homeostatic fluxes in men are still poorly understood.Objective. We investigated the influence of 6 weeks of the SERM raloxifene, an estrogen agonist in bone, but devoid of feminizing actions, on calcium and phosphate metabolism in healthy middle-aged men.Design. In a double-blind, randomized, placebo-controled, cross-over study, we evaluated the influence of 120 mg/day of raloxifene on calciotropic hormones levels, renal tubular reabsorption of calcium and phosphate, and intestinal calcium absorption, as assessed by the calciuric response to an oral calcium load.Results. As compared to the placebo period, raloxifene treatment decreased the response to an oral calcium load, together with a decrease in 1,25(OH)(2)D(3) and in IGF-I serum levels. Maximal renal tubular phosphate reabsorption was decreased in raloxifene-treated men following the calcium load. The renal handling of calcium was not changed.Conclusion. These results are compatible with the hypothesis that raloxifene is associated with lower IGF-I and 1,25(OH)(2)D(3) levels, with consequently reduced intestinal calcium absorption capacity.

Citing Articles

Raloxifene Mitigates Emotional Deficits after Mild Traumatic Brain Injury in Mice.

Honig M, Del Mar N, Moore B, Reiner A Neurotrauma Rep. 2022; 3(1):534-544.

PMID: 36479361 PMC: 9718433. DOI: 10.1089/neur.2022.0052.

Therapeutic Potential of Naringenin Nanosuspension: In Vitro and In Vivo Anti-Osteoporotic Studies.

Gera S, Sampathi S, Maddukuri S, Dodoala S, Junnuthula V, Dyawanapelly S Pharmaceutics. 2022; 14(7).

PMID: 35890343 PMC: 9323949. DOI: 10.3390/pharmaceutics14071449.

Raloxifene as Treatment for Various Types of Brain Injuries and Neurodegenerative Diseases: A Good Start.

Veenman L Int J Mol Sci. 2020; 21(20).

PMID: 33066585 PMC: 7589740. DOI: 10.3390/ijms21207586.

Bazedoxifene improves renal function and increases renal phosphate excretion in patients with postmenopausal osteoporosis.

Masaki H, Imanishi Y, Naka H, Nagata Y, Kurajoh M, Mori K J Bone Miner Metab. 2020; 38(3):405-411.

PMID: 31897746 DOI: 10.1007/s00774-019-01073-1.

Association of serum inorganic phosphate with sex steroid hormones and vitamin D in a nationally representative sample of men.

Wulaningsih W, Van Hemelrijck M, Michaelsson K, Kanarek N, Nelson W, Ix J Andrology. 2014; 2(6):967-76.

PMID: 25270590 PMC: 4324600. DOI: 10.1111/andr.285.

References

Adami S, Gatti D, Bertoldo F, Rossini M, Zamberlan N, Facci E . The effects of menopause and estrogen replacement therapy on the renal handling of calcium. Osteoporos Int. 1992; 2(4):180-5. DOI: 10.1007/BF01623924. View

Ettinger B, Black D, Mitlak B, Knickerbocker R, Nickelsen T, Genant H . Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA. 1999; 282(7):637-45. DOI: 10.1001/jama.282.7.637. View

Van Cromphaut S, Rummens K, Stockmans I, Van Herck E, Dijcks F, Ederveen A . Intestinal calcium transporter genes are upregulated by estrogens and the reproductive cycle through vitamin D receptor-independent mechanisms. J Bone Miner Res. 2003; 18(10):1725-36. DOI: 10.1359/jbmr.2003.18.10.1725. View

van Abel M, Hoenderop J, Dardenne O, St Arnaud R, van Os C, van Leeuwen H . 1,25-dihydroxyvitamin D(3)-independent stimulatory effect of estrogen on the expression of ECaC1 in the kidney. J Am Soc Nephrol. 2002; 13(8):2102-9. DOI: 10.1097/01.asn.0000022423.34922.2a. View

Meinhardt U, Ho K . Modulation of growth hormone action by sex steroids. Clin Endocrinol (Oxf). 2006; 65(4):413-22. DOI: 10.1111/j.1365-2265.2006.02676.x. View

Garnero P, Tsouderos Y, Marton I, Pelissier C, Varin C, Delmas P . Effects of intranasal 17beta-estradiol on bone turnover and serum insulin-like growth factor I in postmenopausal women. J Clin Endocrinol Metab. 1999; 84(7):2390-7. DOI: 10.1210/jcem.84.7.5848. View

McKane W, Khosla S, Burritt M, Kao P, Wilson D, Ory S . Mechanism of renal calcium conservation with estrogen replacement therapy in women in early postmenopause--a clinical research center study. J Clin Endocrinol Metab. 1995; 80(12):3458-64. DOI: 10.1210/jcem.80.12.8530583. View

Oleksik A, Duong T, Pliester N, Asma G, Popp-Snijders C, Lips P . Effects of the selective estrogen receptor modulator, raloxifene, on the somatotropic axis and insulin-glucose homeostasis. J Clin Endocrinol Metab. 2001; 86(6):2763-8. DOI: 10.1210/jcem.86.6.7549. View

Poiraudeau S, Roux C, De Ceuninck F, Tsagris L, Borderie D, Cherruau B . Circulating insulin-like growth factor system changes in women with acute estrogen deficiency induced by GnRH agonist. Osteoporos Int. 1997; 7(5):463-70. DOI: 10.1007/s001980050034. View

10.

Smith M, Fallon M, Lee H, Finkelstein J . Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial. J Clin Endocrinol Metab. 2004; 89(8):3841-6. DOI: 10.1210/jc.2003-032058. View

11.

BOUCHER A, DAmour P, Hamel L, FUGERE P, Gascon-Barre M, LePage R . Estrogen replacement decreases the set point of parathyroid hormone stimulation by calcium in normal postmenopausal women. J Clin Endocrinol Metab. 1989; 68(4):831-6. DOI: 10.1210/jcem-68-4-831. View

12.

Dick I, Devine A, Beilby J, Prince R . Effects of endogenous estrogen on renal calcium and phosphate handling in elderly women. Am J Physiol Endocrinol Metab. 2004; 288(2):E430-5. DOI: 10.1152/ajpendo.00140.2004. View

13.

Caverzasio J, Montessuit C, Bonjour J . Stimulatory effect of insulin-like growth factor-1 on renal Pi transport and plasma 1,25-dihydroxyvitamin D3. Endocrinology. 1990; 127(1):453-9. DOI: 10.1210/endo-127-1-453. View

14.

Sonnet E, Lacut K, Roudaut N, Mottier D, Kerlan V, Oger E . Effects of the route of oestrogen administration on IGF-1 and IGFBP-3 in healthy postmenopausal women: results from a randomized placebo-controlled study. Clin Endocrinol (Oxf). 2007; 66(5):626-31. DOI: 10.1111/j.1365-2265.2007.02783.x. View

15.

Pak C, Kaplan R, Bone H, Townsend J, Waters O . A simple test for the diagnosis of absorptive, resorptive and renal hypercalciurias. N Engl J Med. 1975; 292(10):497-500. DOI: 10.1056/NEJM197503062921002. View

16.

Khosla S, Melton 3rd L, Riggs B . Clinical review 144: Estrogen and the male skeleton. J Clin Endocrinol Metab. 2002; 87(4):1443-50. DOI: 10.1210/jcem.87.4.8417. View

17.

Heshmati H, Khosla S, Burritt M, OFallon W, Riggs B . A defect in renal calcium conservation may contribute to the pathogenesis of postmenopausal osteoporosis. J Clin Endocrinol Metab. 1998; 83(6):1916-20. DOI: 10.1210/jcem.83.6.4854. View

18.

Delmas P, Ensrud K, Adachi J, Harper K, Sarkar S, Gennari C . Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab. 2002; 87(8):3609-17. DOI: 10.1210/jcem.87.8.8750. View

19.

BIJVOET O, MORGAN D, FOURMAN P . The assessment of phosphate reabsorption. Clin Chim Acta. 1969; 26(1):15-24. DOI: 10.1016/0009-8981(69)90280-0. View

20.

Uebelhart B, Herrmann F, Pavo I, Draper M, Rizzoli R . Raloxifene treatment is associated with increased serum estradiol and decreased bone remodeling in healthy middle-aged men with low sex hormone levels. J Bone Miner Res. 2004; 19(9):1518-24. DOI: 10.1359/JBMR.040503. View